Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) EBIT (2023 - 2025)

CG Oncology's EBIT history spans 3 years, with the latest figure at -$48.7 million for Q4 2025.

  • For Q4 2025, EBIT fell 27.99% year-over-year to -$48.7 million; the TTM value through Dec 2025 reached -$190.8 million, down 66.37%, while the annual FY2025 figure was -$190.8 million, 66.37% down from the prior year.
  • EBIT reached -$48.7 million in Q4 2025 per CGON's latest filing, up from -$51.1 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$9.7 million in Q1 2023 to a low of -$51.1 million in Q3 2025.
  • Average EBIT over 3 years is -$30.1 million, with a median of -$27.1 million recorded in 2024.
  • Peak YoY movement for EBIT: crashed 131.14% in 2024, then decreased 27.99% in 2025.
  • A 3-year view of EBIT shows it stood at -$19.4 million in 2023, then crashed by 96.58% to -$38.0 million in 2024, then fell by 27.99% to -$48.7 million in 2025.
  • Per Business Quant, the three most recent readings for CGON's EBIT are -$48.7 million (Q4 2025), -$51.1 million (Q3 2025), and -$48.7 million (Q2 2025).